What happened
Mindray Medical's stock price rose 24.57% in the second half of the year, bringing its market value back above 200 billion yuan and outperforming the CSI 300 index by over 32 percentage points as of September 7.
The company's H1 2026 report showed revenue of 17.747 billion yuan, up 6% year-on-year, the highest growth since Q3 2024. Net profit declined 3.55%, but the drop narrowed significantly from previous quarters.
In its earnings call, Mindray stated that the most difficult phase for the domestic medical device industry has passed, though hospitals still face budget pressures, leading to a weak recovery outlook.
Why it matters
The stock's rebound and improving fundamentals suggest that the medical device sector may be emerging from a prolonged downturn, which could signal a broader recovery for the industry.
Mindray's performance is often seen as a bellwether for the sector; its recovery may indicate improving conditions for other companies in the space.
With valuation at historical lows and expectations of earnings growth, the company could attract renewed investor interest, potentially driving further market gains.
Key facts
Mindray Medical's stock rose 24.57% in H2 2026, with market value exceeding 200 billion yuan.
H1 2026 revenue was 17.747 billion yuan, up 6% year-on-year; net profit was 5.047 billion yuan, down 3.55%.
Excluding exchange rate effects, H1 net profit grew 7.22% year-on-year.
Q2 single-quarter revenue and net profit both turned positive, with operating cash flow of 3.496 billion yuan, up 44%.
The company's TTM P/E ratio stood at 26.07 times, below the 30th percentile historically.
Analysts predict EPS growth of 5.56%, 14.67%, and 13.67% for 2026-2028.
What to watch next
Whether Mindray's domestic business can achieve positive growth for the full year 2026, as the company expects, and if the recovery accelerates into 2027.
The progress of international expansion, particularly in Europe, Latin America, and Asia-Pacific, which are expected to lead growth and increase the share of overseas revenue.
Industry-wide trends such as the impact of volume-based procurement, innovation commercialization, and domestic companies' overseas expansion, which could shape the sector's next growth cycle.